Pharma's Almanac

Since launching in 2015, Pharma’s Almanac, published by Nice Insight, has established itself as a top resource for industry insights. It focuses on the most dynamic markets, active business sectors, and significant players in the pharmaceutical and biotechnology field. Pharma's Almanac is your essential destination for industry news, featuring thorough analyses of research and development, manufacturing, supply chain issues, future technologies, along with daily press releases and weekly news updates. Our website serves as a vibrant hub where informative content meets data. We share our articles through a tri-weekly e-newsletter and also produce a printed magazine every quarter. Our editorial team boasts decades of collective experience in the industry, and with the help of a variety of expert contributors, we ensure that each issue is packed with engaging, fresh, and original information. Pharma’s Almanac was designed to provide key opinion leaders with the insights and data they need to remain competitive in the market.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#1701110

United States

#909566

Health/Biotechnology and Pharmaceuticals

#873

Traffic sources

Monthly visitors

Articles

Building Resilient Pharma Supply Chains in an Uncertain World

3 weeks ago | pharmasalmanac.com | Cynthia Challener

Why Supply Chain Resilience MattersBiopharmaceutical companies must not only develop safe and effective drugs, but ensure reliable supply of those products once they are on the market. That requires ongoing access to sufficient quantities of high-quality raw materials, manufacturing equipment, and components; continued performance of production facilities; and control over storage and distribution, with all activities meeting regulatory compliance requirements.
From Niche to Necessity: How Single-Use Transformed Biomanufacturing

1 month ago | pharmasalmanac.com | Cynthia Challener

Why Single-Use Technologies? Single-use technologies (SUTs) for biopharmaceutical manufacturing find applications today across all aspects of upstream and downstream processing.
Three Decades of Collaboration: Evolution from Basic Partnerships to Complex Open-Innovation Models

1 month ago | pharmasalmanac.com | Cynthia Challener

Historical Focus on IP ProtectionThe birth of the pharmaceutical industry took place in Germany during the mid-19th century, with the United States becoming a major player only in the early 20th century. As the industry matured, competition became fierce, and companies took great measures to protect their research activities and proprietary product data.
From Market Failures to Lifesaving Innovations: The Evolution of Orphan Drugs

1 month ago | pharmasalmanac.com | Cynthia Challener

Convoluted Route to the Orphan Drug Act The first use of the term orphan in relation to drugs occurred in the United States in the 1960s and referred to drugs approved for use in adults but not children, likely due to their limited profitability in the smaller market.1 A few years later, the term orphan was applied to drug substances developed prior to passage in 1962 of the Kefauver–Harris Amendments to the Food, Drug and Cosmetic Act and for drug products that had been previously marketed...
Achieving Scalable and Sustainable Precision Fermentation Using Process Analytical Technology

1 month ago | pharmasalmanac.com | Charlotte Hughes

Transforming Biologics Production with Precision FermentationPrecision fermentation harnesses the capabilities of genetically engineered microorganisms — such as yeasts, fungi, and bacteria — to produce a wide range of high-value biomolecules. When properly optimized, precision fermentation processes enable the production of biologic substances with high yield, purity, and consistency.
30 Years/30 Articles: Continuous Bioprocessing

2 months ago | pharmasalmanac.com | Cynthia Challener

Potential Advantages of Continuous BioprocessingContinuous processing has been leveraged by a variety of industries for many decades, providing a considerable range of benefits, including increased productivity in a smaller footprint, greater process consistency, lower resource consumption and waste generation for reduced environmental impacts, improved quality, reduced costs, and enhanced flexibility to respond to market demands.
Coriolis Pharma Launches U.S. Entity Alongside Innovative Drug Product Platform Service Offerings for Monoclonal Antibodies

May 29, 2024 | pharmasalmanac.com | Nice Insight

Martinsried-Munich, Germany, May 29, 2024 – Coriolis Pharma, a globally operating service provider for R&D and GMP drug product development, R&D and GMP analytics and sterile drug product manufacturing support, announced the launch of a U.S. entity that allows customers to combine the convenience of a local service with the advantages of international expertise.
Bright Outlook for Exosome-Based Therapeutics and Diagnostics Despite Numerous Hurdles

May 8, 2024 | pharmasalmanac.com | Cynthia Challener

Given the difficulty in delivering naked genetic material across cell membranes, it should come as no surprise that the human body has developed its own delivery systems. Extracellular vesicles (EVs) are nanoscale particles comprising lipid bilayers containing cellular material that are secreted by many different types of cells.
How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success

May 8, 2024 | pharmasalmanac.com | Nice Insight

Before initiating human trials for a pharmaceutical product, there is a crucial need to invest in chemistry, manufacturing, and controls (CMC) development to ensure the clinical product meets established quality manufacturing criteria. The main goal of CMC is to ensure the quality of the pharmaceutical product throughout its development stages.
PCI Pharma Services Begins Installation of Sterile Fill-Finish and Lyophilization Line as Part of $100 Million New Facility Expansion

May 2, 2024 | pharmasalmanac.com | Nice Insight

Philadelphia, PA – PCI Pharma Services, (“PCI”) a world leading global contract development and manufacturing organization (CDMO), has begun installation of key equipment for its newest sterile fill-finish facility on the company’s Bedford, NH campus.